Physician

George A Csank, M.D.

According to 2025 Medicare claims, George Csank, M.D. (NPI: 1457383986) practices plastic and reconstructive surgery in the Pittsfield, MA market, with the plurality of this provider's patient population coming from Berkshire, MA. Csank uses personal NPI as billing NPI and primary practice location at 01201-8228. Csank is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Csank's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,784 traditional Medicare patients, billed 8,333 HCPCS/CPT codes, and received $735,981 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 486 prescription claims across 344 beneficiaries totaling $6,881 in drug costs, led by Fluorouracil (Fluorouracil). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $367,857 to $735,981. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,297 to $6,881. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$397K$793K2015 Medicare payment: $367,857 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $407,660 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $407,730 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $551,665 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $579,083 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $525,882 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $793,440 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $732,751 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $640,180 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $735,981 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20156502,580$367,857
20167612,972$407,660
20178473,099$407,730
20181,1465,234$551,665
20191,2626,152$579,083
20201,2154,701$525,882
20211,7886,431$793,440
20221,7527,198$732,751
20231,5576,794$640,180
20241,7848,333$735,981

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$5.2K$10K2015 Drug cost: $2,297 (USD; Tot_Drug_Cst)2016 Drug cost: $1,646 (USD; Tot_Drug_Cst)2017 Drug cost: $2,402 (USD; Tot_Drug_Cst)2018 Drug cost: $10,327 (USD; Tot_Drug_Cst)2019 Drug cost: $7,589 (USD; Tot_Drug_Cst)2020 Drug cost: $6,256 (USD; Tot_Drug_Cst)2021 Drug cost: $6,867 (USD; Tot_Drug_Cst)2022 Drug cost: $7,280 (USD; Tot_Drug_Cst)2023 Drug cost: $7,610 (USD; Tot_Drug_Cst)2024 Drug cost: $6,881 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015157235$2,297
2016159190$1,646
2017149194$2,402
2018225289$10,327
2019227321$7,589
2020246362$6,256
2021308436$6,867
2022253348$7,280
2023259376$7,610
2024344486$6,881

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more558704$93
17110Destruction of skin growth, 1-14 growths360414$81
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more8941,027$63
17000Destruction of precancer skin growth, 1 growth617860$45
17003Destruction of precancer skin growth, 2-14 growths4201,956$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
FluorouracilFluorouracil29856$1,712
CephalexinCephalexin179897$829
MetronidazoleMetronidazole16577$629
Betamethasone DipropionateBetamethasone Dipropionate17568$607
KetoconazoleKetoconazole17700$287

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for George A. Csank, M.D.?

Tedicare shows public-source Medicare data for George A. Csank, M.D. (NPI 1457383986), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does George A. Csank, M.D. have ACO affiliation data?

George A. Csank, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to George A. Csank, M.D.?

A separate primary affiliated billing organization is not shown for this profile in the available data.

Does George A. Csank, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.